Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: A double-blind, randomized, placebo-controlled trial

被引：76

作者：

Kemper, CA

Haubrich, R

Frank, I

Dubin, G

Buscarino, C

McCutchan, JA

Deresinski, SC

机构：

[1] Santa Clara Valley Med Ctr, Div Infect Dis, Dept Med, San Jose, CA 95128 USA

[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[3] Univ Calif San Diego, Antiviral Res Ctr, San Diego, CA 92103 USA

[4] Univ Penn, Dept Med, Philadelphia, PA 19104 USA

[5] GlaxoSmithKline Biol, Collegeville, PA USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2003年 / 187卷 / 08期

关键词：

D O I：

10.1086/374562

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The safety and immunogenicity of inactivated hepatitis A (HepA) vaccine was assessed in 133 hepatitis A virus-seronegative, human immunodeficiency virus (HIV)-infected adults. Patients were randomly assigned to receive, in a blinded fashion, either 2 doses of vaccine (1440 enzyme-linked immunosorbent assay units) or placebo 6 months apart. Seroconversion at month 9 was observed in 68% of those with CD4 cell counts greater than or equal to200 cells/mm(3) but in only 9% of those with lower CD4 cell counts (P = .004). HepA vaccine was well tolerated and had no effect on the course of HIV infection or plasma HIV RNA load.

引用

页码：1327 / 1331

页数：5

共 18 条

[1]

[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1

[2] The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up [J].